The accelerated approval of oncologic drugs: lessons from ponatinib

MeSH terms

• Adverse Drug Reaction Reporting Systems
• Antineoplastic Agents / adverse effects*
• Antineoplastic Agents / therapeutic use
• Drug Approval*
• Government Regulation
• Humans
• Imidazoles / adverse effects*
• Imidazoles / therapeutic use
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
• Public Health
• Pyridazines / adverse effects*
• Pyridazines / therapeutic use
• Time Factors
• United States
• United States Food and Drug Administration